Last reviewed · How we verify
Cefazolin and Moxifloxacin
This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and moxifloxacin (a fluoroquinolone) to inhibit bacterial DNA gyrase and topoisomerase IV, providing broad-spectrum antimicrobial coverage.
This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and moxifloxacin (a fluoroquinolone) to inhibit bacterial DNA gyrase and topoisomerase IV, providing broad-spectrum antimicrobial coverage. Used for Surgical site infection prophylaxis (likely indication given Phase 3 status and combination rationale), Serious gram-positive and gram-negative bacterial infections.
At a glance
| Generic name | Cefazolin and Moxifloxacin |
|---|---|
| Sponsor | University of British Columbia |
| Drug class | Beta-lactam antibiotic + Fluoroquinolone combination |
| Target | Bacterial penicillin-binding proteins (cefazolin); bacterial DNA gyrase and topoisomerase IV (moxifloxacin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Cefazolin is a first-generation cephalosporin that binds penicillin-binding proteins and prevents peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Moxifloxacin is a fourth-generation fluoroquinolone that inhibits bacterial topoisomerases, preventing DNA replication and transcription. Together, they provide synergistic coverage against gram-positive and gram-negative bacteria, likely being evaluated for surgical prophylaxis or serious infections.
Approved indications
- Surgical site infection prophylaxis (likely indication given Phase 3 status and combination rationale)
- Serious gram-positive and gram-negative bacterial infections
Common side effects
- Hypersensitivity/allergic reaction (cefazolin)
- Tendinopathy (moxifloxacin)
- QT prolongation (moxifloxacin)
- Gastrointestinal disturbance
- Photosensitivity (moxifloxacin)
Key clinical trials
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial (NA)
- Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial (PHASE2)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefazolin and Moxifloxacin CI brief — competitive landscape report
- Cefazolin and Moxifloxacin updates RSS · CI watch RSS
- University of British Columbia portfolio CI